MSN Says Novartis Is Using Bad Patent to Stall Entresto Copies

MSN Laboratories Pvt. Ltd. urged a federal judge to order Novartis AG to delist a revived Entresto patent from the FDA’s Orange Book, arguing it doesn’t cover the blockbuster heart drug’s active ingredient and unlawfully blocks competition.

The request came in MSN’s brief supporting its motion for summary judgment to delist US Patent No. 8,101,659 from the US Food and Drug Administration’s registry of approved drugs, both of which were filed Wednesday in the US District Court for the District of Delaware. MSN also filed a response brief opposing Novartis’ motion to dismiss its delisting counterclaim.

The US Court of ...